Esimerkkejä Absolute neutrophil count käytöstä Englanti ja niiden käännökset Suomi
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
ANC absolute neutrophil count.
A new cycle of therapy should not begin until the absolute neutrophil count is≥ 1500/mm3.
ANC absolute neutrophil count.
Do not use in dogs with neutropenia defined as absolute neutrophil count< 2,000 /mm3.
Low absolute neutrophil count ANC.
The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count(ANC) is less than 1.5x109/l.
Absolute neutrophil count(ANC)≥ 1.5 x 109/l.
Increased total bilirubin, b decreased absolute neutrophil count, b hypermagnesaemia, b, hypernatraemiab.
Absolute neutrophil count× decreased(< 1500/ mm³) Λ*°.
Transplantation or patients who are expected to have neutropenia(absolute neutrophil count< 500 cells/ µl) for 10 or more days.
Median Absolute Neutrophil Count cells x 109/l.
One patient in a study of osteoarthritis developed transient neutropenia(absolute neutrophil count< 1 x 109/l) after receiving a very large dose 2000 mg.
ANC absolute neutrophil count a occurring after at least 1 month of treatment.
Profile of Median Pegfilgrastim Serum Concentration and Absolute Neutrophil Count(ANC) in Chemotherapy Treated Patients after a Single 6 mg Injection.
If absolute neutrophil count returns to baseline grade and fever resolves, resume at the same dose level.
Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count(ANC) should be≥ 1,500 cells/mm3 and platelets should be≥ 100,000 cells/mm3.
Absolute neutrophil count ANC> 1.0 x 109/ l for 3 consecutive days Then, if ANC remains> 1.0 x 109/ l for 3 more consecutive days.
The most serious adverse reaction reported in clinical trialswith deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5 x 109/l, which occurred in approximately 1% of patients.
If neutropenia develops 3(absolute neutrophil count< 1.3 x 10/ µl), it may be appropriate to interrupt or discontinue CellCept.
TMZ administration can be continued throughout the 42 day concomitant period(up to 49 days)if all of the following conditions are met: absolute neutrophil count(ANC)≥ 1.5 x 109/l thrombocyte count≥ 100 x 109/l.
Neutropenia(absolute neutrophil count< 500) was generally reversible and was managed by temporarily withholding Jakavi see sections 4.2 and 4.8.
Patients should be monitored formyelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count(ANC) returns to≥ 1500 cells/ mm3 and platelet count returns to≥ 100,000 cells/ mm3.
If neutropenia develops(absolute neutrophil count< 1.3 x 103/ l) it may be appropriate to interrupt or discontinue Mycophenolate mofetil Teva.
Patients should bemonitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count(ANC) returns to≥ 1500 cells/mm3 and platelet count returns to≥ 100,000 cells/mm3.
Neutropenia(absolute neutrophil count[ANC]< 1.5 x 109/l) and leukopenia have been observed with medicinal products that inhibit IL-1, including Ilaris.
Before each cycle, adequate monitoring of complete blood counts should be conducted to verify the absolute neutrophil count(ANC), platelets and haemoglobin as neutropenia, thrombocytopenia and anaemia are frequent adverse reactions of vinflunine.
Neutropenia(absolute neutrophil count[ANC]< 1.5 x 109/l) has been observed commonly with another medicinal product that inhibits IL-1 used in a patient population(rheumatoid arthritis) other than CAPS.
A: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count≥ 1.5 x 109/l; thrombocyte count≥ 100 x 109/l; CTC non- haematological toxicity≤ Grade 1 except for alopecia, nausea, vomiting.
Absolute neutrophil count decreased, blood amylase increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, weight increased, white blood cell count decreased.
Laboratory parameters(including, but not limited to white blood cell count and absolute neutrophil count) should be monitored routinely during BLINCYTO infusion, especially during the first 9 days of the first cycle, and treated appropriately.